

"Express Mail" mailing number.: ET475301827US
Date of Deposit: October 25, 2001
I hereby certify that this paper and all papers and fees referred to herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents, Washington, D.C. Shaylor E. Dunn



RECEIVED

JAN 17 2002

TECH CENTER 1600/2900

PATENT

#14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Daniel et al.

Group Art Unit: 1623

Serial No.: 09/516,728

Examiner: Bansal, G.

Filed: March 1, 2000

Docket No.: 1242/12/2 CIP

Confirmation No.: 2723

For: MODULATION OF ENDOTHELIAL CELL SURFACE RECEPTOR ACTIVITY IN THE REGULATION OF ANGIOGENESIS

STATEMENT THAT SEQUENCE LISTING AND
COMPUTER READABLE COPY ARE THE SAME

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821(f), applicants hereby state that the Sequence Listing information recorded in computer readable form is identical to the written Sequence Listing on paper.

Although a check is being submitted, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number **50-0426**.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 10/25/01

By:

Artes A. Taylor, Jr.
Artes A. Taylor, Jr.
Registration No. 39,395

Suite 1400 University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: (919) 493-8000
Facsimile: (919) 419-0383

Customer No. Bar Code Label:



1242/12/2 AAT/ajm

25297

PATENT TRADEMARK OFFICE

BEST AVAILABLE COPY

no written description for analog or derivative
Fragment is less than the full length

BEST AVAILABLE COPY

09/516728 March 12000.

(copy)
ABSTRACT

C-I-P. of 09/152,160 Septmber 10, 1998. 6248327 Patent X
No prelin Amndt

I Antibody to DEP-1/ECRTP
Claims 1-14.

II Pharmaceutical comp^y comping ECRTP/DEP-1 ^{peptide or element}
15-18 derivatives thereof, kit contain^{ing} ^{pyrophosphate}
38-44.

III a method of screening for a substance that ^{modulates} ~~modulates~~ receptor
tyrosine Kinase.

Claims 19-25 method involves ligand isolated by lysing cells & affint
28-30, 37 purifying

IV A method as above

Claim 26 method involves recombinant method of making the ligand

V Recombinant cell for use in assay of claim 19
Claim 27

VI

March 1 2000

Priority 152160
Sep 10, 1998

09/516728 Election

No Traverse Election Claims 1-14
drawn to antibody.

an antibody. Preferentially binds to ^{ecto domain} ECRT1/DEP-1 or fragments
or derivative of the Ab.

Need Seq in claims.

Claim 1 is drawn to an antibody which preferentially binds
an ECRT1 P/DEP-1

WO 97/30008 teaches an antibody to a DEP1 polypeptide
of Seq ID #2 human DEP1
Also teaches a Type III density enhanced protein tyrosine phosphatase
enzyme

general Ab

1-14
4 9

2, 3, 5, 6, 7, 9, 10, 11, 12, 13

1, 4, 8, 14 > 102(b) sec. claim 23 27

1, 4 ← fragment.
← what's a derivative?

2, 35 preferentially

immunoreaction characteristics

BEST AVAILABLE COPY
COPY



Application No.: ~~08~~ 09/516728

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: If Applicable
Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

TECH CENTER 1600/2900

JAN 17 2002

RECEIVED